Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study

• M. Turgut,
• P. Moreau,
• M. Dimopoulos,
• J. Mikhael,
• K. Yong,
• M. Capra,
• T. Facon,
• R. Hajek,
• I. Spicka,
• M. Risse,
• G. Asset,
• S. Macé,
• T. Martin

Affiliations

M. Turgut

Ondokuz Mayis University, Samsun, Turkey; Corresponding author.

P. Moreau

University Hospital Hôtel-Dieu, Nantes, France

M. Dimopoulos

The National and Kapodistrian University of Athens, Athens, Greece

J. Mikhael

Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, United States

K. Yong

University College Hospital, London, United Kingdom

M. Capra

Hospital Mãe de Deus, Porto Alegre, Brazil

T. Facon

Lille University Hospital, Lille, France

R. Hajek

University Hospital Ostrava, Ostrava, Czech Republic

I. Spicka

Charles University in Prague, Prague, Czech Republic

M. Risse

Sanofi R&D, Vitry/Alfortville, France

G. Asset

Sanofi R&D, Chilly-Mazarin, France

S. Macé

Sanofi R&D, Vitry/Alfortville, France

T. Martin

University of California at San Francisco, San Francisco, United States